Rituxan

Latest stories

6h
FOX Business
Regeneron Pharmaceuticals, Inc. vs. Rochepressure from biosimilars -- generic forms of complex biologic drugs -- in the
Regeneron Pharmaceuticals, Inc. vs. Roche
FOX Business / Posted 6 hours ago
pressure from biosimilars -- generic forms of complex biologic drugs -- in the near future. Sales of cancer therapies Rituxan and Herceptin are still growing by single digits despite first earning FDA approval in 1997 and 1998, respectively.... Read more
6h
FOX Business
Regeneron Pharmaceuticals, Inc. vs. Rochepressure from biosimilars -- generic forms of complex biologic drugs -- in the
Regeneron Pharmaceuticals, Inc. vs. Roche
FOX Business / Posted 6 hours ago
pressure from biosimilars -- generic forms of complex biologic drugs -- in the near future. Sales of cancer therapies Rituxan and Herceptin are still growing by single digits despite first earning FDA approval in 1997 and 1998, respectively.... Read more
11h
Channel NewsAsia
Roche boosted by trial success with blood cancer drugcompany fights the threat of biosimilar competition. Roche said Gazyva proved
Roche boosted by trial success with blood cancer drug
Channel NewsAsia / Posted 11 hours ago
company fights the threat of biosimilar competition. Roche said Gazyva proved significantly better than its older drug Rituxan at delaying the progression of disease in people with previously untreated follicular lymphoma. Clinical trials with... Read more
13h
Channel NewsAsia
Roche announces positive results for Gazyva in phase III studyZURICH: Roche Holding AG said on Friday its drug Gazyva showed superior progres
Roche announces positive results for Gazyva in phase III study
Channel NewsAsia / Posted 13 hours ago
ZURICH: Roche Holding AG said on Friday its drug Gazyva showed superior progression-free survival compared to Mabthera/Rituxan in people with previously untreated follicular lymphoma in the pivotal phase III Gallium study that met is primary endpoint... Read more
14h
Business Wire
Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphomasafety of Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine)
Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma
Business Wire / Posted 14 hours ago
safety of Gazyva® (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan® (rituximab) plus chemotherapy followed by Rituxan alone. Results from a pre-planned interim analysis showed that... Read more
8d
dna
Pfizer's Ibrance shows promise in checking breast cancer progressionattack. The Pfizer drug has already shown encouraging early results against a f
Pfizer's Ibrance shows promise in checking breast cancer progression
dna / Posted 8 days ago
attack. The Pfizer drug has already shown encouraging early results against a form of blood cancer when used with Roche's Rituxan. Researchers are hopeful that combining the two approaches, one that takes the brakes off of the immune system with... Read more
3 related stories
8d
Channel NewsAsia
Pfizer cancer drug shows promise in combo with Merck's Keytrudaattack. The Pfizer drug has already shown encouraging early results against a f
Pfizer cancer drug shows promise in combo with Merck's Keytruda
Channel NewsAsia / Posted 8 days ago
attack. The Pfizer drug has already shown encouraging early results against a form of blood cancer when used with Roche's Rituxan. Researchers are hopeful that combining the two approaches, one that takes the brakes off of the immune system with... Read more
3 related stories
21d
The Mercury News
Rep. Mark DeSaulnier has cancer and plans to seek re-electionas he sat at the Georgetown Lombardi Cancer Center for four- to six-hour stretc
Rep. Mark DeSaulnier has cancer and plans to seek re-election
The Mercury News / Posted 21 days ago
as he sat at the Georgetown Lombardi Cancer Center for four- to six-hour stretches with the chemo -- bendamustine and rituxan -- slowly dripping into his system. He wasn't alone. "There were 25 people in there and you don't know the acuity of... Read more
22d
The Mercury News
Exclusive: Rep. Mark DeSaulnier has cancer and plans to seek re-electionas he sat at the Georgetown Lombardi Cancer Center for four- to six-hour stretc
Exclusive: Rep. Mark DeSaulnier has cancer and plans to seek re-election
The Mercury News / Posted 22 days ago
as he sat at the Georgetown Lombardi Cancer Center for four- to six-hour stretches with the chemo -- bendamustine and rituxan -- slowly dripping into his system. He wasn't alone. "There were 25 people in there and you don't know the acuity of... Read more
24d
Business Wire
Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meetingof one prior treatment with a chemotherapy. Results for Genentech’s hematology
Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire / Posted 24 days ago
of one prior treatment with a chemotherapy. Results for Genentech’s hematology medicines include data from a study of Rituxan® (rituximab) in children with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL). Results... Read more
30d
FOX Business
Exelixis, Inc. vs. Rochesales rose about 4% at a constant exchange rate to about $12.7 billion.Sales gr
Exelixis, Inc. vs. Roche
FOX Business / Posted 30 days ago
sales rose about 4% at a constant exchange rate to about $12.7 billion.Sales growth of its three top-selling products -- Rituxan, Herceptin, and Avastin -- has slowed low single-digits, but the three still produced combined sales of about $5.4... Read more
30d
FOX Business
Exelixis, Inc. vs. Rochesales rose about 4% at a constant exchange rate to about $12.7 billion.Sales gr
Exelixis, Inc. vs. Roche
FOX Business / Posted 30 days ago
sales rose about 4% at a constant exchange rate to about $12.7 billion.Sales growth of its three top-selling products -- Rituxan, Herceptin, and Avastin -- has slowed low single-digits, but the three still produced combined sales of about $5.4... Read more
m
Business Wire
Biogen Reports First Quarter 2016 Revenues of $2.7 Billionchemotherapy followed by Gazyva alone as a new treatment for people with follic
Biogen Reports First Quarter 2016 Revenues of $2.7 Billion
Business Wire / Posted 1 months ago
chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan®-containing regimen, or had their follicular lymphoma return after such treatment. Follicular lymphoma is the most... Read more

People in this news